Active substances: Gabapentin
Several clinical studies have reported the use of ultramicronized PEA um-PEA in the treatment of various syndromes associated with chronic pain that are poorly responsive to standard therapies. The ultramicronization process is often used in the preparation of pharmaceuticals, as it yields a crystalline structure with higher energy content and smaller particle size which contributes to better distribution and diffusion and therefore a greater pharmacological efficacy.
Patients selected for the study were suffering from FBSS caused by laminectomy, discectomy, or vertebral stabilization, who came to our attention complaining of an increase in pain intensity compared to the immediate postoperative condition.
See Table 1 for patient demographics.
To make sure Neurontin is safe for you, tell your doctor if you have ever had: lung disease, such as chronic obstructive pulmonary disease COPD; kidney disease or if you are on dialysis; diabetes; depression, a mood disorder, or suicidal thoughts or actions; a seizure unless you take gabapentin to treat seizures; liver disease; heart disease; or for patients with RLS if you are a day sleeper or work a night shift.
Some people have thoughts about suicide while taking this medicine. Your doctor should check your progress at regular visits.
Your family or other caregivers should also be alert to changes in your mood or symptoms. It is not known whether this medicine will harm an unborn baby.
Tell your doctor if you are pregnant or plan to become pregnant. Seizure control is very important during pregnancy, and having a seizure could harm both mother and baby. Do not start or stop taking Neurontin for seizures without your doctor's advice, and tell your doctor right away if you become pregnant.
Gabapentin can pass into breast milk, but effects on the nursing baby are not known. Aenean venenatis consectetur orci, sit amet ultricies magna sagittis vel.
Nulla non diam nisi, ut ultrices massa.
Pellentesque sed nisl metus. Praesent a mi vel ante molestie venenatis. Ut viverra erat id augue bibendum rutrum. Nam aliquet feugiat molestie. In particular: reduce peripheral nociceptive input muscle relaxants, anti-inflammatory agents, physical therapy; reduce or prevent central sensitization; treat co-morbid conditions that contribute to maintaining a high pain threshold.
At present, treatment of FM favors the use of centrally acting anti-epileptics and antidepressants, since drugs acting peripherally e. Further, PGB was effective in persistent pain refractory to common analgesics and sleep disorders.
Antidepressants, by improving the quality—quantity of sleep, can decrease some associated symptoms such as fatigue and gastrointestinal disorders, thereby contributing to the optimization of analgesia in patients with FM.
Optimal results were achieved by integrating treatments to take advantage of potential drug synergism while assuring a better safety profile, owing to the use of each drug at its lowest effective dose.
An important advance in the field of analgesic treatment for many chronic painful conditions is represented by N- 2-hydroxyethyl esadecanamide palmitoylethanolamide or PEA, a member of the naturally occurring family of fatty acid amides.
For the other two patients, the dose was further increased, with the best response achieved with a daily 1,200 mg dose.